Table 7.
Retrospective data (10 studies).
| Treatment | N | Age Range (Years) | OST pts | PR | SD | Comments | Reference |
|---|---|---|---|---|---|---|---|
| HD chemotherapy and ASCT | 28 | 1–22 | 6 | CR: 3/6 (50%) | 0 | Remission duration: 17, 18, 29 months after ASCT | Choi et al., 2016 [36] |
| HD chemotherapy and ASCT | 19 | 5–16 | 19 | CR: 15/19 | 0 | OS 78.3% EFS 67.4% median follow-up of 31 mo (1–91) |
Hong et al., 2015 [37] |
| Docetaxel + gemcitabine | 28 | 5–20 | 28 | 1/17 (6%) CR: 3/17 (17.5%) ORR: 4/17 (23.5%) |
3/17 (17.5%) | Median response duration 11.2 mo (2.8–14.6) 1-yr-OS rate 35.3 ± 11.6% |
Song et al, 2014 [38] |
| HD thiotepa and ASCT | 53 | 4–31 | 53 | 12/39 (31%) | 18/39 (46%) | mPFS: 8.8 mo(2.3–15.3) mOS: 21.2 mo(8.9–13.4) |
Marec-Berard et al., 2014 [39] |
| Pirarubicin based chemotherapy | 52 | 7–59 | 52 | 13/52 (25%) | 23/52 (44.2%) | Longer mOS with pirarubicin-based chemotherapy vs. gemcitabine-docetaxel treatment: (14.0 vs. 9.0 months, p < 0.05) | He, Qi et al., 2013 [40] |
| gemtabine + docetaxel | 23 | 23 | 13% (3/23) | 8/23 (34.8%) | |||
| Gemcitabine + docetaxel | 19 | 1–22 | 6 | 0 | 2/6 | SD duration for 3 and 9 months in 2 OST pts | Rapkin et al., 2012 [41] |
| salvage gemcitabine + docetaxel | 18 | 12–57 | 18 | 1/18 (5.6%) | 3/18 (17%) | mPFS 2 mo (2–6) mOS: 8 mo (3–21) |
Qi et al., 2012 [42] |
| Gemcitabine + docetaxel | 22 | 8–23 | 17 | 3/17 (17.6%) | 1/17 (6%) | Overall Median response duration 3.5 mo | Navid et al., 2008 [43] |
| Autologous stem cell transplant | 36 | 2–26 | 1 | 0 | 0 | OST patient died | Fraser et al., 2006 [44] |
| HD chemotherapy and ASCT | 15 | 6–21 | 15 | CR: 2/12 (17%) | 2/12 (17%) | 3/15 pts died of toxicity 2/12 pts relapse free at 9 mo 5/12 pts alive at 9 mo |
Sauerbrey et al., 2001 [45] |